<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Bioinformatics</journal-id><journal-title-group><journal-title xml:lang="en">Current Bioinformatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Bioinformatics</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1574-8936</issn><issn publication-format="electronic">2212-392X</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643814</article-id><article-id pub-id-type="doi">10.2174/1574893618666230512141427</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Life Sciences</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Mathematical Modelling and Bioinformatics Analyses of Drug Resistance for Cancer Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Lingling</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Ting</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yulu</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Shanjing</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Tianhai</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff id="aff1"><institution>School of Science, Xian Polytechnic University</institution></aff><aff id="aff2"><institution>School of Mathematics and Big Data, Guizhou Education University</institution></aff><aff id="aff3"><institution>School of Mathematics, Monash University</institution></aff><pub-date date-type="pub" iso-8601-date="2024-03-01" publication-format="electronic"><day>01</day><month>03</month><year>2024</year></pub-date><volume>19</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>211</fpage><lpage>221</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1574-8936/article/view/643814">https://journals.eco-vector.com/1574-8936/article/view/643814</self-uri><abstract xml:lang="en"><p id="idm46041443658672">Cancer is a leading cause of human death worldwide. Drug resistance, mainly caused by gene mutation, is a key obstacle to tumour treatment. Therefore, studying the mechanisms of drug resistance in cancer is extremely valuable for clinical applications.</p><p id="idm46041443662672">:This paper aims to review bioinformatics approaches and mathematical models for determining the evolutionary mechanisms of drug resistance and investigating their functions in designing therapy schemes for cancer diseases. We focus on the models with drug resistance based on genetic mutations for cancer therapy and bioinformatics approaches to study drug resistance involving gene co-expression networks and machine learning algorithms.</p><p id="idm46041443666640">:We first review mathematical models with single-drug resistance and multidrug resistance. The resistance probability of a drug is different from the order of drug administration in a multidrug resistance model. Then, we discuss bioinformatics methods and machine learning algorithms that are designed to develop gene co-expression networks and explore the functions of gene mutations in drug resistance using multi-omics datasets of cancer cells, which can be used to predict individual drug response and prognostic biomarkers.</p><p id="idm46041443671696">:It was found that the resistance probability and expected number of drug-resistant tumour cells increase with the increase in the net reproductive rate of resistant tumour cells. Constrained models, such as logistical growth resistance models, can be used to identify more clinically realistic treatment strategies for cancer therapy. In addition, bioinformatics methods and machine learning algorithms can also lead to the development of effective therapy schemes.</p></abstract><kwd-group xml:lang="en"><kwd>Drug resistance</kwd><kwd>genetic mutation</kwd><kwd>mathematical model</kwd><kwd>combination therapy</kwd><kwd>gene co-expression networks</kwd><kwd>machine learning.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci 2005; 102(27): 9714-9. doi: 10.1073/pnas.0501870102 PMID: 15980154</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53(1): 615-27. doi: 10.1146/annurev.med.53.082901.103929 PMID: 11818492</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>James CE, Hudson AL, Davey MW. Drug resistance mechanisms in helminths: Is it survival of the fittest? Trends Parasitol 2009; 25(7): 328-35. doi: 10.1016/j.pt.2009.04.004 PMID: 19541539</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168(4): 707-23. doi: 10.1016/j.cell.2017.01.017 PMID: 28187290</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 1984; 44(9): 3643-53. PMID: 6744284</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Norton L, Simon R, Brereton HD, Bogden A. Predicting the course of Gompertzian growth. Nature 1976; 264(5586): 542-5. doi: 10.1038/264542a0 PMID: 1004590</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shinoda T, Hayase F, Kato H. Suppression of Cell-cycle Progression during the S Phase of Rat Fibroblasts by 3-Deoxyglucosone, a Maillard Reaction Intermediate. Biosci Biotechnol Biochem 1994; 58(12): 2215-9. doi: 10.1271/bbb.58.2215</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: A novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. J Antimicrob Chemother 2017; 72(10): 2764-8. doi: 10.1093/jac/dkx217 PMID: 29091202</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23(6): 703-13. doi: 10.1038/nm.4333 PMID: 28481359</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Luria SE, Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28(6): 491-511. doi: 10.1093/genetics/28.6.491 PMID: 17247100</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Crump KS, Hoel DG. Mathematical models for estimating mutation rates in cell populations. Biometrika 1974; 61(2): 237-52. doi: 10.1093/biomet/61.2.237</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kimmel M, Axelrod DE. Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics 1990; 125(3): 633-44. doi: 10.1093/genetics/125.3.633 PMID: 2379824</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Goldie JH. Modelling the process of drug resistance. Lung Cancer 1994; 10 (Suppl. 1): S91-6. doi: 10.1016/0169-5002(94)91671-3 PMID: 7916254</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63(11-12): 1727-33. PMID: 526911</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Maeda M, Yamashita H. A numerical approach for a discrete Markov model for progressing drug resistance of cancer. PLOS Comput Biol 2019; 15(2): e1006770. doi: 10.1371/journal.pcbi.1006770 PMID: 30779730</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics 2006; 172(4): 2557-66. doi: 10.1534/genetics.105.049791 PMID: 16636113</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics 2007; 177(4): 2209-21. doi: 10.1534/genetics.107.078915 PMID: 18073428</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2013; 2: e00747.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun 2017; 8(1): 1816. doi: 10.1038/s41467-017-01968-5 PMID: 29180633</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Cunningham JJ, Brown JS, Gatenby RA. Staňková K. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. J Theor Biol 2018; 459: 67-78. doi: 10.1016/j.jtbi.2018.09.022 PMID: 30243754</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 2020; 17(11): 675-86. doi: 10.1038/s41571-020-0411-1 PMID: 32699310</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gu S, Lheureux S, Sayad A, et al. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci USA 2021; 118(25): e2026663118. doi: 10.1073/pnas.2026663118 PMID: 34161278</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Nicholson MD, Antal T. Competing evolutionary paths in growing populations with applications to multidrug resistance. PLOS Comput Biol 2019; 15(4): e1006866. doi: 10.1371/journal.pcbi.1006866 PMID: 30986219</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hori SS, Tong L, Swaminathan S, et al. A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. Sci Rep 2021; 11(1): 1341. doi: 10.1038/s41598-020-78947-2</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Saini A, Gallo JM. Epigenetic instability may alter cell state transitions and anticancer drug resistance. PLOS Comput Biol 2021; 17(8): e1009307. doi: 10.1371/journal.pcbi.1009307 PMID: 34424912</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yin A, Hasselt JG, Guchelaar HJ, et al. Anti-cancer treatment schedule optimization based on tumour dynamics modelling incorporating evolving resistance. Sci Rep 2022; 12: 1-14. doi: 10.1038/s41598-022-09014-1</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tutsoy O. Pharmacological, non-pharmacological policies and mutation: An artificial intelligence based multi-dimensional policy making algorithm for controlling the casualties of the pandemic diseases. IEEE Trans Pattern Anal Mach Intell 2022; 44(12): 9477-88. doi: 10.1109/TPAMI.2021.3127674 PMID: 34767503</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Tutsoy O, Polat A. Linear and non-linear dynamics of the epidemics: System identification based parametric prediction models for the pandemic outbreaks. ISA Trans 2022; 124: 90-102. doi: 10.1016/j.isatra.2021.08.008 PMID: 34412892</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>William P, Wang TY, Riely GJ, et al. Kras mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2018; 2: e17-45.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Shamieh SE, Saleh F, Assaad S, et al. Next-generation sequencing reveals mutations in rb1, cdk4 and tp53 that may promote chemo-resistance to palbociclib in ovarian cancer. Drug Metabol Therapy 2019; p. 34.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Färkkilä A, Rodríguez A, Oikkonen J, et al. Heterogeneity and clonal evolution of acquired parp inhibitor resistance in tp53-and brca1-deficient cells. Cancer Res 2021; 81(10): 2774-87. doi: 10.1158/0008-5472.CAN-20-2912 PMID: 33514515</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumour-suppressor genes in carcinogenesis: A review. Anticancer Res 2020; 40(11): 6009-15. doi: 10.21873/anticanres.14622 PMID: 33109539</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>King MC, Wilson AC. Evolution at two levels in humans and chimpanzees. Science 1975; 188(4184): 107-16. doi: 10.1126/science.1090005 PMID: 1090005</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150(2): 264-78. doi: 10.1016/j.cell.2012.06.023 PMID: 22817890</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 2015; 76(6): 1113-32. doi: 10.1007/s00280-015-2861-1 PMID: 26391154</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8(8): 579-91. doi: 10.1038/nrc2403 PMID: 18596824</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346(6216): 1480-6. doi: 10.1126/science.1254721 PMID: 25394791</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Coldman A, Goldie J. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 1986; 48(3-4): 279-92. doi: 10.1016/S0092-8240(86)90028-5 PMID: 3828558</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Goldie JH, Coldman AJ. Drug resistance in cancer: Mechanisms and models. J Biol Chem 1998; 938: 142-53.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Coldman AJ, Goldie JH. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Biosci 1983; 65(2): 291-307. doi: 10.1016/0025-5564(83)90066-4</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Komarova N. Stochastic modeling of drug resistance in cancer. J Theor Biol 2006; 239(3): 351-66. doi: 10.1016/j.jtbi.2005.08.003 PMID: 16194548</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Komarova NL, Wodarz D. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies. Cancer Res 2009; 69(11): 4904-10. doi: 10.1158/0008-5472.CAN-08-1959 PMID: 19458080</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Michor F, Nowak M, Iwasa Y. Evolution of resistance to cancer therapy. Curr Pharm Des 2006; 12(3): 261-71. doi: 10.2174/138161206775201956 PMID: 16454743</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol 2014; 355: 10-20. doi: 10.1016/j.jtbi.2014.02.025 PMID: 24681298</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol 2010; 263(2): 179-88. doi: 10.1016/j.jtbi.2009.11.022 PMID: 20004211</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLOS Comput Biol 2009; 5(11): e1000557. doi: 10.1371/journal.pcbi.1000557 PMID: 19893626</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Harnevo LE, Agur Z. The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math Biosci 1991; 103(1): 115-38. doi: 10.1016/0025-5564(91)90094-Y PMID: 1804437</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Sun X, Bao J, Shao Y. Mathematical modeling of therapy induced cancer drug resistance: connecting cancer mechanisms to population survival rates. Sci Rep 2016; 6(1): 22498. doi: 10.1038/srep22498 PMID: 26928089</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Ghosh M, Chandra P, Sinha P, Shukla JB. Modelling the spread of bacterial infectious disease with environmental effect in a logistically growing human population. Nonlinear Anal Real World Appl 2006; 7(3): 341-63. doi: 10.1016/j.nonrwa.2005.03.005</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Nakasu S, Nakasu Y, Fukami T, Jito J, Nozaki K. Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neurooncol 2011; 102(2): 303-10. doi: 10.1007/s11060-010-0319-1 PMID: 20686821</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Anderson ARA, Hassanein M, Branch KM, et al. Microenvironmental independence associated with tumor progression. Cancer Res 2009; 69(22): 8797-806. doi: 10.1158/0008-5472.CAN-09-0437 PMID: 19887618</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Tomasetti C, Levy D. Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci 2010; 107(39): 16766-71. doi: 10.1073/pnas.1007726107 PMID: 20826440</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Komarova NL, Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS One 2007; 2(10): e990. doi: 10.1371/journal.pone.0000990 PMID: 17912367</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol 2011; 3(1): 17-30. doi: 10.1039/C0IB00046A PMID: 20944865</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Fu F, Nowak MA, Bonhoeffer S. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLOS Comput Biol 2015; 11(3): e1004142. doi: 10.1371/journal.pcbi.1004142 PMID: 25789469</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119(10): 3000-10. doi: 10.1172/JCI38746 PMID: 19759520</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Kars MD. Işeri ÖD, Gündüz U, Ural AU, Arpaci F, Molnár J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006; 26(6B): 4559-68. PMID: 17201178</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Picco N, Sahai E, Maini PK, Anderson ARA. Integrating models to quantify environment-mediated drug resistance. Cancer Res 2017; 77(19): 5409-18. doi: 10.1158/0008-5472.CAN-17-0835 PMID: 28754669</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Tian T, Chen A, Zhou T. Integrated pinelines for inferring gene regulatory networks from single cell data. Curr Bioinform 2022; 17(7): 559-64. doi: 10.2174/1574893617666220511234247</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6(10): 813-23. doi: 10.1038/nrc1951 PMID: 16990858</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-61. PMID: 23180760</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013; 45(10): 1113-20. doi: 10.1038/ng.2764 PMID: 24071849</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015; 5(11): 1210-23. doi: 10.1158/2159-8290.CD-15-0235 PMID: 26482930</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 2019; 569(7757): 503-8. doi: 10.1038/s41586-019-1186-3 PMID: 31068700</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Tate JG, Bamford S, Jubb HC, et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res 2019; 47(D1): D941-7. doi: 10.1093/nar/gky1015 PMID: 30371878</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Cui H, Kong H, Peng F, et al. Inferences of individual drug response-related long non-coding RNAs based on integrating multi-omics data in breast cancer. Mol Ther Nucleic Acids 2020; 20: 128-39. doi: 10.1016/j.omtn.2020.01.038 PMID: 32163894</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Zhang Z, Li D, Zhang H, et al. Inferences from dysregulated long non-coding RNA-mediated competing endogenous RNAs in various chemotherapy drugs and evaluation of drug response in breast cancer. Mol Ther Nucleic Acids 2020; 20: 128-39.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Oh M, Park S, Lee S, et al. DRIM: A web-based system for investigating drug response at the molecular level by condition-specific multi-omics data integration. Front Genet 2020; 11: 564792. doi: 10.3389/fgene.2020.564792 PMID: 33281870</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Deng Y, Zhang F, Liu J, et al. Development and validation of a prognostic signature based on autophagy-related long non-coding RNA analysis in hepatocellular carcinoma. Front Med 2021; 8: 762570. doi: 10.21203/rs.3.rs-378004/v1</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Zhao T, Xu J, Liu L, et al. Computational identification of epigenetically regulated lncRNAs and their associated genes based on integrating genomic data. FEBS Lett 2015; 589(4): 521-31. doi: 10.1016/j.febslet.2015.01.013 PMID: 25616131</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Xu Y, Dong Q, Li F, et al. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data. J Transl Med 2019; 17(1): 255. doi: 10.1186/s12967-019-2010-4 PMID: 31387579</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Chen BJ, Causton HC, Mancenido D, Goddard NL, Perlstein EO, Peer D. Harnessing gene expression to identify the genetic basis of drug resistance. Mol Syst Biol 2009; 5(1): 310. doi: 10.1038/msb.2009.69 PMID: 19888205</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Qi W, Zhang Q. Genes co-expression network and experimental validation of molecular markers associated with the drug resistance of gastric cancer. Biomarkers Med 2020; 14(9): 761-73. doi: 10.2217/bmm-2019-0504 PMID: 32715733</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Wang Y, Chen L, Ju L, et al. Novel biomarkers associated with progression and prognosis of bladder cancer identified by co-expression analysis. Front Oncol 2019; 9: 1030. doi: 10.3389/fonc.2019.01030 PMID: 31681575</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Liu S, Wu J, Feng Y. The Prediction of Anti-cancer Drug Response by Integrating Multi-omics Data In International Conference on Intelligent Automation and Soft Computing. Cham: Springer Cham. 2021; 5: pp. 1149-56.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Li YK, Hsu HM, Lin MC, et al. Genetic co-expression networks contribute to creating predictive model and exploring novel biomarkers for the prognosis of breast cancer. Sci rep-UK 2021; 11: 1-13.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Neog Bora P, Baruah VJ, Borkotokey S, et al. Identifying the salient genes in microarray data: A novel game theoretic model for the co-expression network. Diagnostics 2020; 10(8): 586-93. doi: 10.3390/diagnostics10080586 PMID: 32823765</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Li Z, Cai S, Li H, et al. Developing a lncRNA signature to predict the radiotherapy response of lower-grade gliomas using co-expression and ceRNA network analysis. Front Oncol 2021; 11: 622880. doi: 10.3389/fonc.2021.622880 PMID: 33767991</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Yao C, Chen BH, Joehanes R, et al. Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes. Circulation 2015; 131(6): 536-49. doi: 10.1161/CIRCULATIONAHA.114.010696 PMID: 25533967</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Zhang J, Zhu W, Wang Q, Gu J, Huang LF, Sun X. Differential regulatory network-based quantification and prioritization of key genes underlying cancer drug resistance based on time-course RNA-seq data. PLOS Comput Biol 2019; 15(11): e1007435. doi: 10.1371/journal.pcbi.1007435 PMID: 31682596</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Zhao Y, Chen J, Freudenberg JM, Meng Q, Rajpal DK, Yang X. Network-based identification and prioritization of key regulators of coronary artery disease loci. Arterioscler Thromb Vasc Biol 2016; 36(5): 928-41. doi: 10.1161/ATVBAHA.115.306725 PMID: 26966275</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Gonçalves JP, Francisco AP, Mira NP, et al. TFRank: network-based prioritization of regulatory associations underlying transcriptional responses. Bioinformatics 2011; 27(22): 3149-57. doi: 10.1093/bioinformatics/btr546 PMID: 21965816</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol 2022; 23(1): 40-55. doi: 10.1038/s41580-021-00407-0 PMID: 34518686</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>You Y, Lai X, Pan Y, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther 2022; 7(1): 156. doi: 10.1038/s41392-022-00994-0 PMID: 35538061</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Frejno M, Zenezini Chiozzi R, Wilhelm M, et al. Pharmacoproteomic characterisation of human colon and rectal cancer. Mol Syst Biol 2017; 13(11): 951. doi: 10.15252/msb.20177701 PMID: 29101300</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Frejno M, Meng C, Ruprecht B, et al. Proteome activity landscapes of tumor cell lines determine drug responses. Nat Commun 2020; 11(1): 3639. doi: 10.1038/s41467-020-17336-9 PMID: 32686665</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Kong J, Lee H, Kim D, et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat Commun 2020; 11(1): 5485. doi: 10.1038/s41467-020-19313-8 PMID: 33127883</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Liu R, Zhang G, Yang Z. Towards rapid prediction of drug-resistant cancer cell phenotypes: single cell mass spectrometry combined with machine learning. Chem Commun (Camb) 2019; 55(5): 616-9. doi: 10.1039/C8CC08296K PMID: 30525135</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Yu L, Zhou D, Gao L, Zha Y. Prediction of drug response in multilayer networks based on fusion of multiomics data. Methods 2021; 192: 85-92. doi: 10.1016/j.ymeth.2020.08.006 PMID: 32798653</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Choi J, Park S, Ahn J. RefDNN: A reference drug based neural network for more accurate prediction of anticancer drug resistance. Sci rep-UK 2020; 10: 1-11. doi: 10.1038/s41598-020-58821-x</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Zhu Y, Brettin T, Evrard YA, et al. Ensemble transfer learning for the prediction of anti-cancer drug response. Sci rep-UK 2020; 10: 1-11. doi: 10.1038/s41598-020-74921-0</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Wang H, Zhao Y, Wu Y, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011; 32(32): 8281-90. doi: 10.1016/j.biomaterials.2011.07.032 PMID: 21807411</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Yu C, Liu X, Yang J, et al. Combination of immunotherapy with targeted therapy: Theory and practice in metastatic melanoma. Front Immunol 2019; 10: 990. doi: 10.3389/fimmu.2019.00990 PMID: 31134073</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Wu XY, Ma W, Gurung K, Guo CH. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy. J Formos Med Assoc 2013; 112(3): 115-24. doi: 10.1016/j.jfma.2012.09.017 PMID: 23473523</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Xiao Y, Yin C, Wang Y, et al. FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. Mol Oncol 2018; 12(6): 883-95. doi: 10.1002/1878-0261.12200 PMID: 29633504</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Garber K. Melanoma combination therapies ward off tumor resistance. Nat Biotechnol 2013; 31(8): 666-7. doi: 10.1038/nbt0813-666b PMID: 23929325</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Hu CMJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83(8): 1104-11. doi: 10.1016/j.bcp.2012.01.008 PMID: 22285912</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Gevertz JL, Aminzare Z, Norton KA, et al. Emergence of anticancer drug resistance: Exploring the importance of the microenvironmental niche via a spatial model. Springer 2015; 158: 1-34. doi: 10.1007/978-1-4939-2782-1_1</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Lefebvre G, Cornelis F, Cumsille P, Colin T, Poignard C, Saut O. Spatial modelling of tumour drug resistance: The case of GIST liver metastases. Math Med Biol 2017; 34(2): 151-76. PMID: 27034422</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Florence D, Thomas L, Sylvain G. Evolutionary epidemiology of drug resistance, a spatial model. PLOS Comput Biol 2014; 5: e1000337.</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Jackson TL, Byrne HM. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumours to chemotherapy. Math Biosci 2000; 164: 0-38.</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 2019; 575(7782): 299-309. doi: 10.1038/s41586-019-1730-1 PMID: 31723286</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134(5): 703-7. doi: 10.1016/j.cell.2008.08.021 PMID: 18775299</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation>Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99(19): 1441-54. doi: 10.1093/jnci/djm135 PMID: 17895480</mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation>Wu A, Loutherback K, Lambert G, et al. Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci 2013; 110(40): 16103-8. doi: 10.1073/pnas.1314385110 PMID: 24046372</mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation>Feinerman O, Veiga J, Dorfman JR, Germain RN, Altan-Bonnet G. Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science 2008; 321(5892): 1081-4. doi: 10.1126/science.1158013 PMID: 18719282</mixed-citation></ref></ref-list></back></article>
